Publicação científica trimestral do CREMERJ

41 Tratamento do diabetes tipo 2: tendências atuais Alessandra Saldanha de Mattos Matheus Med. Ciên. e Arte , Rio de Janeiro, v.1, n.1, p.25-44, jan-mar 2022 REFERÊNCIAS 1. International Diabetes Federation, IDF Diabetes Atlas, nineth edition, International Diabetes Federation, Brussels, Belgium, 2019. 2. Khunti K, S. Seidu. Therapeutic inertia and the legacy of dysglycemia on the microvascular and macrovascular complications of diabetes. Diabetes Care 2019; 42 :349-351. 3. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evi-dence from across the world in 2007–2017. Cardiovasc Diabetol 2018; 17:83. 4. Davies MJ, D’Alessio DA, Fradkin J et al. Management of hyperglycemia in Type 2 diabetes. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41: 2669-2701. 5. Van Bruggen R, Gorter K, Stolk RP et al. Refill adherence and polypharmacy among patients with type 2 diabetes in general practice, Pharmacoepidemiol Drug Saf 2009; 18: 983-991. 6. Bertoluci et al. Portuguese‑Brazilian evidence‑based guideline on the management of hyperglycemia in type 2 diabetes mellitus. Diabetol Metab Syndr 2020; 12:45. 7. Seidua S, Cosb X, Bruntonc S et al. A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe Primary Care. Diabetes 2021; 15: 31–51. 8. Diabetes Advocacy: Standards of Medical Care in Diabetes 2021. Diabetes Care 2021;44(Suppl. 1):S221-S222. 9. Landgraf R, Aberle J, Birkenfeld AL et al. Therapy of Type 2 Diabetes- Exp Clin Endocrinol Diabetes 2019; 127 (Suppl 1): S73-S92. 10. The Look AHEAD Research Group Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369: 145-154. 11. The Look AHEAD Research Group Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2diabetes: A post-hoc analysis of the Look AHEAD randomized clinical trial. Lancet Diabetes Endocrinol 2016; 4: 913-921. 12. Riddle MC, Cefalu WT, Evans PH et al. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. J Clin Endocrinol Metab. 2021 Aug 30:dgab585. doi: 10.1210/clinem/dgab585. Epub ahead of print. PMID: 34459898. 13. Miller E, Aguilar RB, Herman ME, Schwartz SS. - Type 2 diabetes: Evolving concepts and treatment Cleveland Clinic Journal of Medicine 2019; E 86(7). 14. Sun L, Xie C, Wang G, et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med 2018 Dec. 24 (12):1919-29. 15. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999; 281(21):2005-12. 16. Kooy A, de Jager J, Lehert P et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009 Mar 23. 169(6):616-25. 17. Yin M, Zhou J, Gorak EJ, Quddus F. Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta analysis. Oncologist. 2013 Nov 20. 18. Alfayez OM, Al Yami MS, Alshibani M et al. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs. Prim Care Diabetes. 2019 Jan 31. 19. ADVANCE Collaborative Group, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560–72.